Year: 2022

Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg

Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee...

error: Content is protected !!